Mediwound LTD Schedule 13G passive stakes

T. Rowe Price Associates, Inc. has reported beneficial ownership of 5.5% of MediWound Ltd's common stock as of March 31, 2026.

T. Rowe Price Associates, Inc. has reported a 4.3% beneficial ownership stake in MediWound Ltd. as of December 31, 2025.

Hungarian investment fund HOLD Alapkezelo Zrt. has reported a beneficial ownership of 8.1% in MediWound Ltd., holding 1,039,954 common shares.

Rosalind Advisors and related entities have updated their beneficial ownership in MediWound Ltd. to 7.0% of common shares, including warrants subject to a blocker provision.

Yelin Lapidot Holdings Management and its principals have disclosed a 5.95% beneficial ownership stake in MediWound Ltd. as of December 31, 2025.

T. Rowe Price Associates, Inc. has reported a 5.5% beneficial ownership stake in MediWound Ltd, holding 614,503 shares of common stock.

Rosalind Advisors, Inc. and affiliated entities reported a 7.0% beneficial ownership stake in MediWound Ltd., including common shares and warrants.

Hungarian investment fund HOLD Alapkezelo Zrt. has reported a 6.5% beneficial ownership stake in MediWound Ltd., holding 703,429 common shares.

Rosalind Advisors and affiliated entities have updated their beneficial ownership in MediWound Ltd. to 5.2% of common shares, totaling 570,326 shares.

Rosalind Advisors, Inc., along with affiliated entities and individuals, has filed an amended Schedule 13G disclosing a 6.1% beneficial ownership stake in MediWound Ltd., totaling 670,158 common shares.

Rosalind Advisors, Inc., Rosalind Master Fund L.P., and associated individuals have disclosed a combined 7.2% passive beneficial ownership stake in MediWound Ltd., totaling 791,315 common shares, as of December 31, 2024.